Restore Prescription Drugs Discount Act
- Bill Number
- S. 2099
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-17: Read twice and referred to the Committee on the Judiciary.
- Last Updated
- 2025-07-21T19:32:26Z
AI-Generated Summary
Purpose of the Legislation
This bill, titled the "Restore Prescription Drugs Discount Act," aims to eliminate the Robinson-Patman Act of 1936 (RPA), an antitrust law that restricts price discrimination—meaning sellers cannot charge different prices to different buyers if it harms competition. The repeal is intended to allow greater flexibility in pricing practices, particularly to restore discounts on prescription drugs and promote competition in that sector.
Key Provisions
- Repeal of the RPA: The bill fully repeals the entire Robinson-Patman Act (15 U.S.C. 13a et seq.) and all amendments made by it, effective upon enactment.
- No additional provisions are included; the bill is limited to this single action.
Significant Changes to Existing Law
- The RPA, enacted in 1936, prohibits sellers from offering different prices, discounts, or terms to competing buyers when it could injure competition (e.g., large retailers getting better deals than small ones). Repealing it removes these federal restrictions entirely, shifting reliance to other antitrust laws like the Clayton Act or Sherman Act for addressing unfair pricing.
- This would end federal enforcement of RPA-specific rules, which have been rarely used in recent decades but still apply in cases involving commodities like groceries and pharmaceuticals.
Potential Impacts
- On Government Agencies: The Federal Trade Commission (FTC) and Department of Justice (DOJ), which enforce antitrust laws, would lose authority over RPA violations, potentially simplifying their workload but reducing tools to protect smaller businesses from discriminatory pricing.
- On Citizens: Consumers, especially those buying prescription drugs, could benefit from increased discounts and lower prices due to freer competition among sellers. However, it might lead to higher prices for some if larger buyers gain more advantages.
- On International Relations: Minimal direct impact, as the RPA is a domestic law focused on U.S. commerce; it could indirectly affect global supply chains for pharmaceuticals by easing U.S. pricing rules.
Main Stakeholders Affected
- Businesses and Retailers: Large retailers and manufacturers (e.g., pharmacies like Walmart or CVS) would gain flexibility to offer volume discounts without RPA challenges, potentially boosting efficiency. Small businesses and independent retailers, previously protected by the RPA from being undercut, might face increased competition.
- Pharmaceutical Industry: Drug wholesalers and producers could more easily provide discounts to certain buyers, aiming to lower costs for patients and insurers.
- Consumers and Patients: Primary beneficiaries in the prescription drug market through potential price reductions, though broader retail sectors (e.g., groceries) could see varied pricing effects.
- Antitrust Enforcers: FTC and DOJ would adapt by focusing on other laws, possibly leading to fewer investigations into price discrimination.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: The repeal simplifies antitrust enforcement by eliminating an outdated law often criticized for stifling competition; however, it could invite more private lawsuits under remaining antitrust statutes if pricing practices lead to monopolistic behavior. Courts would no longer interpret or apply RPA precedents.
- Constitutional Implications: None significant, as repealing a statute is a standard congressional power and does not raise First Amendment, due process, or other constitutional concerns.
- Political Implications: This bill reflects a deregulatory approach favoring free-market pricing, potentially appealing to pro-business interests but drawing criticism from advocates for small businesses who view the RPA as a safeguard against corporate dominance. Its focus on prescription drugs ties into ongoing debates on healthcare affordability.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2025-06-17: Read twice and referred to the Committee on the Judiciary.
- 2025-06-17: Introduced in Senate
Bill Versions
- Restore Prescription Drugs Discount Act — issued 2025-06-17 — PDF (1 pages)